NASDAQ:AGEN Agenus (AGEN) Stock Price, News & Analysis $6.56 +0.59 (+9.88%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$6.00▼$6.6550-Day Range$5.97▼$17.7352-Week Range$4.78▼$32.00Volume760,084 shsAverage Volume761,397 shsMarket Capitalization$137.76 millionP/E RatioN/ADividend YieldN/APrice Target$31.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Agenus alerts: Email Address Agenus MarketRank™ Stock AnalysisAnalyst RatingHold2.17 Rating ScoreUpside/Downside372.6% Upside$31.00 Price TargetShort InterestBearish11.99% of Float Sold ShortDividend StrengthN/ASustainability-0.93Upright™ Environmental ScoreNews Sentiment-0.08Based on 14 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($10.73) to ($9.76) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.31 out of 5 starsMedical Sector150th out of 936 stocksBiological Products, Except Diagnostic Industry16th out of 154 stocks 4.1 Analyst's Opinion Consensus RatingAgenus has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 1 buy rating, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageAgenus has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Agenus' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.99% of the float of Agenus has been sold short.Short Interest Ratio / Days to CoverAgenus has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Agenus has recently increased by 1.27%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAgenus does not currently pay a dividend.Dividend GrowthAgenus does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAgenus has received a 72.61% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Agenus is -0.93. Previous Next 2.2 News and Social Media Coverage News SentimentAgenus has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Agenus this week, compared to 3 articles on an average week.Search Interest63 people have searched for AGEN on MarketBeat in the last 30 days. This is an increase of 215% compared to the previous 30 days.MarketBeat Follows8 people have added Agenus to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Agenus insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of Agenus is held by insiders.Percentage Held by Institutions61.46% of the stock of Agenus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Agenus' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Agenus are expected to grow in the coming year, from ($10.73) to ($9.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agenus is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agenus is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Agenus' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research... But today, the author of Get Rich with Dividends is feeling extra generous...Click here now to claim your FREE copy of Marc's AI playbook. About Agenus Stock (NASDAQ:AGEN)Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Read More AGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AGEN Stock News HeadlinesJuly 26 at 4:21 PM | finance.yahoo.comThe Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin PharmaceuticalJuly 26 at 4:21 PM | finance.yahoo.comAgenus to Provide Second Quarter 2024 Financial Report and Corporate UpdateJuly 27, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.July 26 at 2:31 PM | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agenus Inc. - AGENJuly 24 at 2:35 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agenus Inc. - AGENJuly 22, 2024 | prnewswire.comAGEN Investors Have Opportunity to Join Agenus Inc. Securities Fraud Investigation with the Schall Law FirmJuly 22, 2024 | americanbankingnews.comAgenus Inc. (NASDAQ:AGEN) Receives $31.00 Consensus Target Price from BrokeragesJuly 21, 2024 | msn.comJefferies Downgrades Agenus (AGEN)July 27, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.July 21, 2024 | americanbankingnews.comJefferies Financial Group Reiterates Hold Rating for Agenus (NASDAQ:AGEN)July 21, 2024 | americanbankingnews.comAgenus (NASDAQ:AGEN) Cut to "Neutral" at HC WainwrightJuly 20, 2024 | markets.businessinsider.comHold Rating Justified for Agenus Amidst Regulatory Uncertainties and Mixed Clinical ResultsJuly 20, 2024 | msn.comAgenus stock plummets over 50% as FDA rejects accelerated approval for BOT/BAL cancer therapyJuly 20, 2024 | americanbankingnews.comAgenus (NASDAQ:AGEN) Downgraded to Hold at Baird R WJuly 19, 2024 | finanznachrichten.deAgenus Inc.: Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal CancerJuly 19, 2024 | marketwatch.comAgenus Shares Sink After FDA Discourages Accelerated ApprovalJuly 19, 2024 | finance.yahoo.comAgenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal CancerJuly 19, 2024 | markets.businessinsider.comNavigating Uncertainty: Hold Rating on Agenus Amidst FDA Hurdles and Efficacy QuestionsSee More Headlines Receive AGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:AGEN CUSIP00847G70 CIK1098972 Webagenusbio.com Phone(781) 674-4400Fax781-674-4200Employees440Year FoundedN/APrice Target and Rating Average Stock Price Target$31.00 High Stock Price Target$100.00 Low Stock Price Target$7.00 Potential Upside/Downside+370.4%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($12.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-245,760,000.00 Net Margins-154.88% Pretax Margin-154.88% Return on EquityN/A Return on Assets-77.55% Debt Debt-to-Equity RatioN/A Current Ratio0.24 Quick Ratio0.24 Sales & Book Value Annual Sales$156.31 million Price / Sales0.89 Cash FlowN/A Price / Cash FlowN/A Book Value($7.78) per share Price / Book-0.85Miscellaneous Outstanding Shares21,000,000Free Float20,033,000Market Cap$138.39 million OptionableOptionable Beta1.32 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Garo H. Armen Ph.D. (Age 71)Founder, Executive Chairman & CEO Comp: $1.34MMs. Christine M. Klaskin (Age 58)VP of Finance, Principal Financial Officer & Principal Accounting Officer Comp: $407.44kDr. Steven J. O'Day M.D. (Age 63)Ph.D., Chief Medical Officer Comp: $970.98kCraig WinterChief Information OfficerMr. Zack ArmenHead of Investor RelationsMs. Tracy Mazza ClementeChief People OfficerMr. Alfred DadsonChief Manufacturing OfficerMr. Eric HumesChief Quality OfficerDr. Todd Jude Yancey M.D.Member of Advisory Board & Chief Strategic AdvisorDr. Robin G. Taylor M.B.A.Ph.D., Chief Commercial OfficerMore ExecutivesKey CompetitorsAthira PharmaNASDAQ:ATHAPrecision BioSciencesNASDAQ:DTILAligos TherapeuticsNASDAQ:ALGSAdaptimmune TherapeuticsNASDAQ:ADAPOyster Point PharmaNASDAQ:OYSTView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpSold 1,296,809 shares on 7/26/2024Ownership: 0.427%Hennion & Walsh Asset Management Inc.Sold 528,287 shares on 7/20/2024Ownership: 0.144%Values First Advisors Inc.Sold 319,428 shares on 7/19/2024Ownership: 0.079%Key Client Fiduciary Advisors LLCSold 789,215 shares on 7/16/2024Ownership: 0.332%Price T Rowe Associates Inc. MDBought 123,058 shares on 5/15/2024Ownership: 1.704%View All Insider TransactionsView All Institutional Transactions AGEN Stock Analysis - Frequently Asked Questions How have AGEN shares performed this year? Agenus' stock was trading at $16.5580 at the beginning of the year. Since then, AGEN shares have decreased by 60.4% and is now trading at $6.56. View the best growth stocks for 2024 here. How were Agenus' earnings last quarter? Agenus Inc. (NASDAQ:AGEN) released its quarterly earnings results on Tuesday, May, 7th. The biotechnology company reported ($3.04) EPS for the quarter, beating the consensus estimate of ($3.58) by $0.54. The biotechnology company had revenue of $28.01 million for the quarter, compared to the consensus estimate of $40.70 million. When did Agenus' stock split? Agenus's stock reverse split on the morning of Friday, April 12th 2024. The 1-20 reverse split was announced on Friday, April 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Garo H. Armen's approval rating as Agenus' CEO? 2 employees have rated Agenus Chief Executive Officer Garo H. Armen on Glassdoor.com. Garo H. Armen has an approval rating of 56% among the company's employees. This puts Garo H. Armen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. Who are Agenus' major shareholders? Top institutional shareholders of Agenus include Bank of New York Mellon Corp (0.43%), Key Client Fiduciary Advisors LLC (0.33%), Hennion & Walsh Asset Management Inc. (0.14%) and Values First Advisors Inc. (0.08%). Insiders that own company stock include Agenus Inc, Garo H Armen, Steven J O'day and Christine M Klaskin. View institutional ownership trends. How do I buy shares of Agenus? Shares of AGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Agenus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Agenus investors own include (ROSG) (ROSG), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), OPKO Health (OPK), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA). This page (NASDAQ:AGEN) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agenus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agenus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
